Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06604767

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

A Phase 1, Dose-Escalation, Randomized, Active-Controlled, Modified Double-Blind, Parallel-Group, Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
390 (actual)
Sponsor
Sanofi Pasteur, a Sanofi Company · Industry
Sex
All
Age
60 Years
Healthy volunteers
Accepted

Summary

The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.

Detailed description

The study duration will be up to approximately 12 months minus the screening period.

Conditions

Interventions

TypeNameDescription
BIOLOGICALparainfluenza virus type 3 vaccine (PIV3)Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
BIOLOGICALRSV/hMPV/PIV3 vaccinePharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
BIOLOGICALRSV/hMPV vaccinePharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
BIOLOGICALRSV vaccine 1Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
BIOLOGICALRSV vaccine 2Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

Timeline

Start date
2024-09-17
Primary completion
2026-03-25
Completion
2026-03-25
First posted
2024-09-19
Last updated
2026-01-22

Locations

8 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT06604767. Inclusion in this directory is not an endorsement.